Shanghai Medicilon Inc. (SHA:688202)

Market Cap	7.59B +97.9%
Revenue (ttm)	1.26B +20.6%
Net Income	-137.67M
EPS	-1.05
Shares Out	131.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,584,297
Open	59.65
Previous Close	59.64
Day's Range	57.38 - 60.73
52-Week Range	30.03 - 84.70
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2,504
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688202

Financial Performance

In 2025, Shanghai Medicilon's revenue was 1.16 billion, an increase of 12.08% compared to the previous year's 1.04 billion. Losses were -167.83 million, -49.27% less than in 2024.